Stability and Formulation of Erlotinib in Skin Creams.
Olmsted
dermatology
drug repurposing
erlotinib
rare disease
skin cancer
stability indicating
topical
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
05 Feb 2022
05 Feb 2022
Historique:
received:
16
01
2022
revised:
02
02
2022
accepted:
03
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Recent studies have highlighted the benefit of repurposing oral erlotinib (ERL) treatment in some rare skin diseases such as Olmsted syndrome. The use of a topical ERL skin treatment instead of the currently available ERL tablets may be appealing to treat skin disorders while reducing adverse systemic effects and exposure. A method to prepare 0.2% ERL cream, without resorting to a pure active pharmaceutical ingredient, was developed and the formulation was optimized to improve ERL stability over time. Erlotinib extraction from tablets was incomplete with Transcutol, whereas dimethyl sulfoxide (DMSO) allowed 100% erlotinib recovery. During preliminary studies, ERL was shown to be sensitive to oxidation and acidic pH in solution and when added to selected creams (i.e., Excipial, Nourivan Antiox, Pentravan, and Versatile). The results also showed that use of DMSO (5%
Identifiants
pubmed: 35164335
pii: molecules27031070
doi: 10.3390/molecules27031070
pmc: PMC8839675
pii:
doi:
Substances chimiques
Antioxidants
0
Ethylene Glycols
0
Tablets
0
carbitol
A1A1I8X02B
Erlotinib Hydrochloride
DA87705X9K
Dimethyl Sulfoxide
YOW8V9698H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA Dermatol. 2020 Feb 1;156(2):191-195
pubmed: 31895432
J Pharmacol Toxicol Methods. 2011 Mar-Apr;63(2):209-15
pubmed: 21059397
J Thorac Oncol. 2010 Sep;5(9):1477-80
pubmed: 20736807
Expert Opin Pharmacother. 2001 Jul;2(7):1167-75
pubmed: 11583067
PDA J Pharm Sci Technol. 2014 5/6;68(3):221-238
pubmed: 25188345
J Dermatolog Treat. 2019 Dec;30(8):760-771
pubmed: 30668185
Dermatology. 2012;225(2):179-82
pubmed: 23095682
N Engl J Med. 2005 Jul 14;353(2):133-44
pubmed: 16014883
Int J Antimicrob Agents. 2020 Sep;56(3):106083
pubmed: 32659465
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
J Pain Res. 2019 Apr 29;12:1189-1192
pubmed: 31118747
Cancer. 2018 May 15;124(10):2169-2173
pubmed: 29579331
Water Res. 2015 Nov 15;85:103-13
pubmed: 26311272